{"doi":"10.1002/jpr3.70131","title":"Preliminary evidence of improved liver biomarkers in adolescents with obesity and suspected metabolic dysfunction‐associated steatotic liver disease treated with semaglutide: A case series","abstract":"Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects 30%–40% of youth with obesity and lacks approved pharmacologic therapies. In this single‐center retrospective case series at a tertiary care safety‐net children's hospital, we evaluated five adolescents (mean age: 17.0 years; 100% Hispanic; 60% male; mean body mass index: 50.8 kg/m²) treated with semaglutide for ≥3 months. Baseline liver enzymes and fibrosis marker (mean ± standard deviation) included alanine aminotransferase (ALT): 107.4 ± 26.8 IU/L, aspartate aminotransferase (AST): 64.6 ± 16.2 IU/L, and AST to platelet ratio index (APRI): 0.41 ± 0.07. After treatment, values decreased to ALT: 69.0 ± 17.9 IU/L, AST: 43.6 ± 8.8 IU/L, and APRI: 0.28 ± 0.05. Reduction in ALT ( p < 0.01), AST ( p < 0.01) and APRI ( p = 0.01) were all statistically significant. These findings suggest semaglutide may improve hepatic inflammation and fibrosis in adolescents with MASLD. Larger prospective studies are needed to confirm these early signals in high‐risk pediatric populations.","journal":"JPGN Reports","year":2025,"id":586375,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8203,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1501017,"name":"Katya Fomenko","orcid":null,"position":1,"is_corresponding":false},{"id":1501018,"name":"Fotini T. Mitsinikos","orcid":null,"position":2,"is_corresponding":false},{"id":401844,"name":"Alaina P. Vidmar","orcid":"0000-0003-3790-6255","position":3,"is_corresponding":false},{"id":1276433,"name":"Rachel B. Schenker","orcid":"0000-0003-0488-6147","position":0,"is_corresponding":true}],"reference_count":8,"raw_metadata":null,"created_at":"2026-07-19T02:59:28.666390Z","pmid":"42110146","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}